$0.24
(Market cap
$89 Mln
Revenue (TTM)
$1 Mln
P/E Ratio
2.1
P/B Ratio
0.9
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0.6 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-1.4
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$7.8
-
Face value
--
-
Shares outstanding
5,310,499
5 Years Aggregate
CFO
$-200.15 Mln
EBITDA
$-232.08 Mln
Net Profit
$-230.61 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Rallybio Corp (RLYB)
| 210.6 | 6.1 | 17.9 | 297.1 | -27.4 | -30.2 | -- |
|
BSE Sensex*
| -9.1 | -1.5 | 2.9 | -3.6 | 5.9 | 6.0 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Rallybio Corp (RLYB)
| -28.5 | -59.5 | -63.6 | -31.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Rallybio Corp (RLYB)
|
17.0 | 89.3 | 0.7 | 45.6 | 4,167.0 | 59.8 | 2.1 | 0.9 |
| 82.4 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 70.9 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.6 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 106.5 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 359.4 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 540.0 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 594.0 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 350.3 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 147.8 | 9,339.4 | 282.0 | 82.9 | -28.6 | 11.4 | 140.1 | 11.5 |
Shareholding Pattern
View DetailsAbout Rallybio Corp (RLYB)
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an... inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut. Read more
-
Co-Founder & Executive Chairman
Dr. Martin W. MacKay Ph.D.
-
Co-Founder & Executive Chairman
Dr. Martin W. MacKay Ph.D.
-
Headquarters
New Haven, CT
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Rallybio Corp (RLYB)
What is the current share price of Rallybio Corp (RLYB) Today?
The share price of Rallybio Corp (RLYB) is $17.05 (NASDAQ) as of 31-Aug-2026 16:00 EDT. Rallybio Corp (RLYB) has given a return of -27.45% in the last 3 years.
What is the current PB & PE ratio of Rallybio Corp (RLYB)?
The P/E ratio of Rallybio Corp (RLYB) is 2.10 times as on 28-Aug-2026.
The P/B ratio of Rallybio Corp (RLYB) is 0.94 times as on 28-Aug-2026, a 82 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.40 |
0.06 |
2024 |
-0.09 |
0.09 |
2023 |
-0.16 |
0.11 |
2022 |
-0.44 |
0.17 |
2021 |
-0.76 |
0.20 |
What is the 52 Week High and Low of Rallybio Corp (RLYB)?
The 52-week high and low of Rallybio Corp (RLYB) are Rs 17.57 and Rs 3.67 as of 01-Sep-2026.
What is the market cap of Rallybio Corp (RLYB)?
Rallybio Corp (RLYB) has a market capitalisation of $ 89 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Rallybio Corp (RLYB)?
Before investing in Rallybio Corp (RLYB), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.